#Singapore #George Clinical #Emerald Clinical Trials #clinical research organization

Emerald Clinical Trials: A New Era for a Veteran in Clinical Research

Emerald Clinical Trials, previously known as George Clinical, has officially unveiled its rebranding effort, marking a significant evolution in its identity as a leading global Clinical Research Organization (CRO). This strategic change reinforces the company's commitment to enhancing clarity and trust within the realm of clinical research, as it embarks on its next chapter of providing preeminent services across various therapeutic areas.

The transformation into Emerald Clinical Trials is more than just a change of name. It signifies a deep commitment to bolstering the industry standards of clinical trials by prioritizing innovations aimed at improving patient quality of life. For over two decades, the company has made strides in mitigating risks associated with global clinical development through extensive therapeutic expertise and local knowledge.

Emerald Clinical Trials continues to offer comprehensive services in numerous therapeutic fields, including noteworthy accomplishments in oncology and cardiometabolic disease therapy. Notably, the organization has established a strong foothold in the Asia-Pacific region alongside formidable global scientific leadership. This diverse operational reach spans direct presence in 42 countries, enhancing efficacy and consistency in clinical study execution worldwide.

Mary Gunn, CEO of Emerald Clinical Trials, stated, "Over the last two decades, we have been dedicated to delivering high-quality trials that combine global reach with a tailored approach to each project. Our capacity to provide the extensive resources characteristic of larger CROs, coupled with the flexibility typical of smaller firms, uniquely positions us to support clients—from burgeoning biotech startups to major pharmaceutical corporations."

As the company seeks to extend its influence, the new branding accentuates Emerald's remarkable achievements and sophisticated experience, which will resonate with an even broader spectrum of stakeholders. This demonstrates a staunch commitment to patients, clients, and collaborative partners.

The emphasis on a client-oriented approach positions Emerald Clinical Trials as a trustworthy ally in the clinical research sphere. The firm’s knack for delivering predictability and reliability in clinical study execution is reinforced by a consistent record of successful transactions, industry awards, and the effective market launch of various therapies.

Dr. Daniel Tillett, CEO of Race Oncology, shared his experience, expressing that early on, they opted to collaborate with a CRO that would offer tailored solutions to unique project needs. "Agility is crucial for biopharmaceutical companies needing responsive partners. Emerald's core strength lies in its ability to adapt quickly without getting bogged down by bureaucratic inefficiencies."

The renaming to Emerald Clinical Trials encapsulates the ambition to redefine what a modern CRO can achieve, seamlessly blending innovation, responsibility, and commitment to quality. With an array of research capabilities at its fingertips, Emerald is well poised to navigate the complexities of the clinical trial landscape.

Emerald Clinical Trials, based in Singapore, serves over 100 biotech firms and six out of the top ten global pharmaceutical corporations. With operational expertise and a commitment to scientific excellence, Emerald provides a full suite of clinical trial services worldwide, innovating solutions across all research phases.

For more information about Emerald Clinical Trials, visit Emerald Clinical or contact media representative Shannon Severino at +1 412 608 2393 for any inquiries. The future points to a robust partnership, reinforcing Emerald's status as a dedicated and resourceful partner in the ever-evolving field of clinical trials.